Fanconi D2 (FANCD2) is monoubiquitinated on K561 (FANCD2-Ub) in response to DNA double-strand breaks (DSBs) to stimulate repair of these potentially lethal DNA lesions. (S222A) phosphorylation-defective mutant (deficient in stimulation of intra-S phase checkpoint, but proficient in DSB repair), but not FANCD2(K561R) monoubiquitination-defective mutant (proficient in stimulation of intra-S phase checkpoint, but deficient in DSB repair) reduced the number of DSBs and facilitated proliferation of BCR-ABL1 positive FANCD2À/À cells. We hypothesize that FANCD2-Ub has an important role in BCR-ABL1 leukemogenesis because of its ability to facilitate the repair of numerous ROS-induced DSBs.
Introduction
Chronic myeloid leukemia in chronic phase (CML-CP) and a cohort of acute lymphoblastic leukemia are characterized by the presence of the Philadelphia chromosome (Ph) that results from a (9;22)(q34;q11) reciprocal translocation, which juxtaposes a portion of the c-abl oncogene 1 (ABL1) gene on chromosome 9 with a fragment of the breakpoint cluster region (BCR) gene on chromosome 22, generating the BCR-ABL1 fusion oncogene. 1 BCR-ABL1 kinase stimulates oxidative DNA damage such as 8-oxoguanine (8-oxoG) and increases the number of DNA double-strand breaks (DSBs) in CML-CP cells. [2] [3] [4] In addition, BCR-ABL1-mediated stimulation of activation-induced cytidine deaminase is responsible for elevation of DNA damage in Phpositive acute lymphoblastic leukemia (ALL) and in CML lymphoblastic phase. 5, 6 These potentially lethal DNA lesions may present a significant obstacle for leukemia cell survival. Thus, repair of the elevated levels of DNA lesions may have an essential role in survival of CML cells. In support of this hypothesis, it has been reported that cells undergo DNA damage-dependent apoptotic crisis during v-ABL1-mediated transformation. 7 Similar mechanisms may operate in BCR-ABL1-induced leukemias, allowing only survival of leukemia cells, which can repair numerous DNA lesions. 8 BCR-ABL1 stimulates three major mechanisms to repair numerous DNA DSBs in leukemia cells: homologous recombination repair (HRR), non-homologous end-joining (NHEJ) and single-strand annealing (SSA). 2, 4, [9] [10] [11] Among the various DNA repair proteins, Fanconi anemia D2 (FANCD2) has the unique ability to affect all of these DSB repair pathways. [12] [13] [14] Accordingly, FANCD2 may have an important role in BCR-ABL1 positive leukemias.
Inactivating mutations in Fanconi anemia (FA) genes cause congenital disorders characterized by chromosomal instability, hypersensitivity to DNA cross-linking agents and increased predisposition to cancer. 15 A total of 13 FA genes have been identified and cloned (A, B, C, D1(BRCA2), D2, E, F, G, I, J, L, M and N); these gene products cooperate in a common cellular pathway to protect the genome from DNA damage. 16 Following DNA damage, key events in the FA pathway are phosphorylation and monoubiquitination of FANCI and FANCD2, which form a heterodimer co-localizing in nuclear foci considered to be DNA repair structures. [17] [18] [19] [20] FANCD2 is monoubiquitinated on K561 (FANCD2-Ub) after DNA damage induced by cross-linking agents, ionizing radiation and endogenous stresses such as reactive oxygen species (ROS). 16, 21, 22 FANCD2-Ub depends on a nuclear complex consisting of FANCA, B, C, E, F, G, L and M, which harbors E3 ubiquitin ligase activity. FANCD2-Ub is then targeted to DSBs to have an essential role in their repair via HRR and SSA. 12 Although FANCD2 appeared to inhibit the third major DSB repair pathwayFDNA protein kinase-mediated NHEJ (D-NHEJ) Fit may stimulate the PARP-1-dependent back-up pathway (B-NHEJ). 13, 14 In addition, FANCD2 is phosphorylated on S222 (FANCD2-pS222) by ATM kinase.
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FANCD2-Ub and FANCD2-pS222 are independent post-translational modifications of the FANCD2 protein regulating discrete cellular signaling pathways. Monoubiquitination on K561 is essential for targeting FANCD2 to DSB repair sites, whereas phosphorylation on S222 is important for activation of the S phase checkpoint.
Because of its role in response to DNA damage, the FA pathway has a pivotal role in protecting genome stability and cancer prevention. The cumulative incidence of tumors in persons with FA mutations was 39-76% by the age of 40-48 years, 10-37% of which were hematologic malignancies. [23] [24] [25] Acute myeloid leukemia (AML), myelodysplastic syndrome and ALL were most common in FA patients; conversely, CML and Ph-positive ALL cases have not been detected.
Here we show that, in contrary to the common dogma that loss of FA pathway may contribute to carcinogenesis, FANCD2-Ub has an important role in BCR-ABL1-mediated leukemogenesis by protecting leukemia cells from the lethal effect of excessive oxidative DNA damage.
Materials and methods

Cells
The SV40-transformed lymphoblast cell line lacking FANCD2 protein expression PD20(FA-D2) and PD20F, PD20F(S222A), PD20F(K561R) cells with restored FANCD2 wild-type (wt), S222A mutant or K561R mutant protein expression, respectively, were kindly provided by Dr Alan D D'Andrea (DanaFarber Cancer Institute, Boston, MA, USA) and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum. 26 Human hematopoietic cell lines Mo7e and UT7, and their p210BCR-ABL1-positive counterparts were described before and cultured in Iscove's modified Dulbecco medium (StemCell Technologies, Vancouver, Canada), supplemented with 10% fetal bovine serum and 5 ng/ml recombinant human granulocyte-macrophage colony-stimulating factor. 27 CML cells were obtained from bone marrow after receiving informed consent according to institutional guidelines from the Stem Cell and Leukemia Core Facility of the University of Pennsylvania (Philadelphia, PA, USA) and the Institute of Hematology and Blood Transfusions in Warsaw (Warsaw, Poland). CD34 þ cells were selected through the use of human CD34 þ selection cocktail (StemCell Technologies). CD34 þ normal bone marrow cells (BMCs) were commercially available (Cambrex BioScience Walkersville, MD, USA). CD34 þ cells were maintained in Iscove's modified Dulbecco medium supplemented with 10% fetal bovine serum with the addition of growth factors: 10pg/ml GM-CSF, 10pg/ml G-CSF, 10 ng/ml SCF, 10 ng/ml LIF, 10 ng/ml MIP-1a, 0.2 ng/ml IL-6 (PeproTech Inc., Rocky Hill, NJ, USA and StemCell Technologies). Murine BMCs from FANCD2 knockout (FANCD2À/À) or wt ( þ / þ ) mice on a mixed 129S4 and C57BL/6J background (kindly provided by Dr Marcus Grompe, Oregon Health and Science University, Portland, OR, USA 28 ) were maintained in Iscove's modified Dulbecco medium supplemented with 10% fetal bovine serum, in the presence of recombinant interleukin-3 (IL-3) and 10 ng/ml SCF. 
Western analysis
Cells were lysed in 1 Â sodium dodecyl sulfate sample buffer by boiling for 3 min, followed by sonication for 10-15 s. Cell lysates were examined by western blotting, using antibodies recognizing the following proteins: FANCD2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), FANCL, USP1, RAD51 (Upstate Biotechnology, Lake Placid, NY, USA), tubulin, ABL1 (Calbiochem) and Ku80 (AbD Serotec, Raleigh, NC, USA).
Retroviral infections
Infections were performed as previously described with modifications. 29 In brief, helper-free retroviruses pMIG-IRES-GFP, pMIG-p210BCR-ABL1-IRES-GFP and pMIG-p210BCR-ABL1(K1172)-IRES-GFP (kindly provided by Dr W Pear, University of Pennsylvania, Philadelphia, PA, USA 30 ), and also pMMP-puro, pMMP-FANCD2(wt)-puro, pMMP-FANCD2(K561R)-puro and pMMP-FANCD2(S222A)-puro (kindly provided by Dr Alan D D'Andrea 31 ) were generated in the Phoenix amphotropic packaging cell line. Supernatants containing viral particles were centrifuged for 3 h at 20 000 rpm and used to infect mononuclear BMCs from 5-fluorouracil pre-treated (i.p. 150 mg/kg) FANCD2À/À or þ / þ mice. In addition, these retroviral supernatants were used to infect PD20(FA-D2), PD20F, PD20F-S222A and PD20F-K561R lymphoblast cell lines. GFP þ cells were sorted using MoFlo High-speed Sorter (Dako Cytomation, Carpinteria, CA, USA).
RNA interference
To downregulate FANCD2, siGENOME SMART pool M-016376-02-5 siRNA (accession number NM_001018115) was used (Thermo Fisher Scientific, Lafayette, CO, USA); scrambled RNA was used as control. Transfection of siRNA was carried out using Amaxa nucleoporation system and Amaxa Human CD34 þ Nucleofector Kit (Lonza, Cologne, Germany), according to manufacturer's protocol. Downregulation of FANCD2 protein expression by siRNA was confirmed 48 h later by western blot.
Immunofluorescence
Nuclear localization of g-H2AX, FANCD2 and RAD51 was detected by immunofluorescence, as previously described. 32 Briefly, cytospins were fixed in PBS with 0.06% Triton X-100 and 4% formaldehyde, washed in PBS and 0.06% Triton X-100, and blocked in washing buffer supplemented with 1% bovine serum albumin. Cells were stained with first antibodies against FANCD2 (Santa Cruz Biotechnology), g-H2AX (Upstate Biotechnology) or RAD51 (Oncogene Research Products, Cambridge, MA, USA). Secondary antibodies conjugated with Alexa Fluor 488 or Alexa Fluor 568 was applied (Molecular Probes, Eugene, OR, USA). Negative controls were performed without primary antibodies. DNA was counterstained with DAPI (4 0 ,6 0 diamedino-2-phenylindole). Specific staining was visualized using an inverted Olympus IX70 fluorescence microscope equipped with Â 100 UPlan Apo lens (numeric aperture 1.35) and a Cooke Sensicam QE camera (The Cooke Company, Auburn Hills, MI, USA). At least 25 individual cells were analyzed per experimental group. Images were acquired with Slidebook 3.0 (Intelligent Imaging Innovations, Denver, CO, USA). All graphic adjustments were performed using Adobe Photoshop (Adobe Systems, San Jose, CA, USA).
Leukemogenesis in SCID mice
Outbred SCID mice (Taconic Farms, Germantown, NY, USA) were injected intravenously with 5 Â 10 4 PD20(FA-D2)-BCR-ABL1 or PD20F-BCR-ABL1 cells. Leukemia development was 
Proliferation assays
GFP þ BCR-ABL1-positive FANCD2 þ / þ , FANCD2À/À and FANCD2À/À( þ ) (FANCD2À/À cells transfected with pMMP-FANCD2(wt)-puro BMCs, and Mo7e, Mo7e-BCR-ABL1 and CML CD34 þ cells transfected with FANCD2-specific siRNA and scrambled RNA, were plated in methylcellulose and colonies were counted as described before. 29 MMC, NAC and VE were added when indicated. Proliferation of the parental and BCR-ABL1-positive PD20(FA-D2), PD20F, PD20F(S222A) and PD20F(K561R) was determined in trypan blue exclusion test. For the competition assay, 2 Â 10 5 GFP þ PD20(FA-D2)-BCR-ABL1 or PD20F-BCR-ABL1 cells were mixed with equal number of their GFPÀPD20(FA-D2) or PD20F counterparts. Total number of cells and number of GFP þ cells were counted using Olympus Ix70 fluorescence microscope and the ratio of GFP positive per total number of cells was calculated.
Comet assay
Comet assay was performed as described, with modifications. 33, 34 Cells were drained in agarose and covered with enzyme buffer (control) or with the enzyme (1 mg/ml endonuclease III (EndoIII) or formamidopyrimidine-DNA glycosylase (Fpg)) in buffer, and incubated for 30 min at 37 1C. Comet tail moment was analyzed in 100 randomly selected images. As our measurement system was not calibrated, tail moment was presented in arbitrary units. Data were analyzed using the Statistica (StatSoft, Tulsa, OK, USA) statistical package. Results obtained with buffer only were subtracted from these obtained with enzyme.
Results
Enhanced expression of FANCD2-Ub in BCR-ABL1 leukemia cells responding to ROS and MMC
Western analysis indicated that Mo7e-BCR-ABL1 leukemia cells and CD34 þ cells from CML-CP and CML in blast phase (CML-BP) patient cells contained more FANCD2-Ub protein than normal counterparts (Figure 1a) , which was associated with enhanced nuclear foci formation by FANCD2-Ub (Figure 1b ) (nuclear foci are generated exclusively by FANCD2-Ub 35 ). These effects in Mo7e-BCR-ABL1 leukemia cells were not associated with their enhanced proliferation (data not shown) nor caused by deregulated expression of FANCD2 ubiquitinase FANCL or downregulation of FANCD2 deubiquitinase USP1 (Figures 1c and d, respectively ), but were reversed after inhibition of BCR-ABL1 kinase with imatinib and reduction of ROS with antioxidants VE and NAC (Figures 1a and b , and Supplementary Figure 1) .
MMC is being routinely used to diagnose FA (FA patient cells are over-sensitive to cross-linking agents such as MMC) and to test the function of FA protein network resulting in FANCD2-Ub. 22 MMC-treated UT7-BCR-ABL1 and Mo7e-BCR-ABL1 cells displayed bigger increase of FANCD2-Ub in comparison with parental UT7 and Mo7e cells (Figure 2a) . MMC treatment enhanced also the expression of FANCD2-Ub in CD34 þ CML-CP and CML-BP cells (Figure 2b ). Downregulation of FANCD2 by siRNA increased the sensitivity Mo7e-BCR-ABL1 cells to MMC (Figure 2c ), suggesting that FANCD2 has an essential role in response to DNA damage in CML.
FANCD2 supports the growth of BCR-ABL1 leukemia cells
To directly test the role of FANCD2 in BCR-ABL1-induced leukemogenesis the SV40-transformed lymphoblast cell line lacking FANCD2 protein expression PD20(FA-D2) and PD20F cells with restored expression of FANCD2 wt protein were transfected with p210BCR-ABL1 (Supplementary Figure 2) . BCR-ABL1 kinase-positive PD20(FA-D2) cells displayed reduced proliferation rate in comparison with PD20(FA-D2) parental cells and BCR-ABL1 kinase-positive PD20F cells ( Figure 3a) ; this effect was associated with an increase of the percentage of sub-G1 apoptotic cells in PD20(FA-D2) þ BCR-ABL1 cells in comparison with PD20 þ BCR-ABL1 cells (10.7 ± 6.1 and 1.7 ± 0.9, respectively, P ¼ 0.027).
Next, equal numbers of GFPÀ PD20(FA-D2) or PD20F cells and GFP þ BCR-ABL1-transformed counterparts were mixed together and cultured. BCR-ABL1 kinase-positive FANCD2-negative cells displayed a clear growth disadvantage in comparison with their BCR-ABL1 kinase-negative counterparts, as indicated by decreasing percentage of GFP þ cells (Figure 3b ). At the same time, BCR-ABL1 kinase did not exert an anti-proliferative effect in PD20F cells expressing FANCD2. The in vitro proliferative defect of BCR-ABL1 kinase-positive FANCD2-negative lymphoblast cells was accompanied by delayed leukemogenesis in SCID mice (Figure 3c ). BCR-ABL1-mediated growth inhibition in the absence of FANCD2 was depended upon BCR-ABL1 kinase activity, because BCR-ABL1(K1172R) kinase-dead mutant did not exert this effect (Figure 3d ).
Next, we examined which function of FANCD2, K561 ubiquitination-dependent DSB repair and/or S222 phosphorylation-induced S phase checkpoint is required to support proliferation of BCR-ABL1-positive cells. Expression of FANCD2 wt (proficient in DNA repair and S phase checkpoint) and FANCD2 phosphorylation-less S222A mutant (proficient in DNA repair, but deficient in S phase checkpoint) rescued the growth of BCR-ABL1-positive FANCD2-deficient cells (Figure 3e ). In contrast, expression of FANCD2 monoubiquitination-deficient K561R mutant (defective in DSB repair, but proficient in S phase checkpoint) did not restore the growth of BCR-ABL1-positive FANCD2-deficient cells. Altogether, these results strongly suggest that FANCD2-Ub has a significant role in the growth of BCR-ABL1-positive leukemia cells.
In support for this hypothesis, the clonogenic potential of BCR-ABL1-positive FANCD2À/À BMCs was reduced by approximately 10-fold in comparison with BCR-ABL1-positive FANCD2 þ / þ counterparts (Figure 4a ). The growth defect was dependent on BCR-ABL1; non-transformedÀ/À and þ / þ BMCs displayed similar clonogenic activities stimulated by SCF þ GM-CSF (data not shown). Restoration of FANCD2 expression 'rescued' the impaired clonogenic activity of BCR-ABL1-positive FANCD2À/À cells. The presence or absence of FANCD2 did not affect the population of BCR-ABL1-positive stem cell-enriched Lin-Kit þ Sca1 þ and early progenitorenriched Lin-Kit þ Sca1À populations in clonogenic cells (Supplementary Figure 3) .
CML-CP and CML-BP patient cells were used to determine the role of FANCD2 in primary leukemia cells. Downregulation of FANCD2 by siRNA in CD34 þ cells from CML-CP and CML-BP inhibited their clonogenic potential (Figure 4b ). 
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In addition, FANCD2-Ub inhibitor, DDN, reduced the clonogenic potential of CD34 þ CML-CP and CML-BP cells (Figure 4c) . DDN inhibits accumulation of FANCD2-Ub and formation of FANCD2 nuclear foci without disruption of the upstream FA core complex. 36 Although DDN may have other targets, these data implicate FANCD2-Ub in BCR-ABL1-induced leukemias.
FANCD2-Ub protects BCR-ABL1-positive cells from ROS-induced DSBs to support leukemogenesis
BCR-ABL1 kinase stimulates repair of numerous ROS-induced DSBs.
2,4,37 Although FANCD2 has a major role in DSB repair, it may be involved in facilitation of DSB repair to protect leukemia cells from the anti-proliferative and/or lethal effect of DSBs. 16 To test this hypothesis, we measured ROS and oxidative DNA damage in BCR-ABL1-positive FANCD2-deficient cells (PD20(FA-D2) þ BCR-ABL1) and in BCR-ABL1-positive FANCD2-proficient cells (PD20F þ BCR-ABL1). Although the presence or absence of FANCD2 did not have an impact on ROS (Figure 5a ), PD20(FA-D2) þ BCR-ABL1 cells accumulated more DNA lesions than PD20F þ BCR-ABL1 cells, as detected by comet assay (Figure 5b ). More specifically, PD20(FA-D2) þ BCR-ABL1 cells did not contain more oxidized bases (Figure 5c ), but they accumulated an excess of DSBs (Figure 5d ) in comparison with PD20F þ BCR-ABL1 cells. In addition, the number of DSBs in PD20(FA-D2) þ BCR-ABL1 cells was reduced after expression of FANCD2 wt and the cell-cycle regulation defective FANCD2(S222A) mutant, but not of the DSB repair-deficient FANCD2(K561R) mutant (Figure 5d ).
These results clearly implicated the role of FANCD2-Ub in protection of BCR-ABL1-positive leukemia cells from the potential lethal effect of an excess of ROS-induced DSBs. This speculation is further supported by the data showing that inhibition of ROS by VE and NAC (Supplementary Figure 4) reduced accumulation of DSBs in PD20(FA-D2) þ BCR-ABL1 cells (Figure 5e ), which was associated with their accelerated proliferation (Figure 5f ).
Discussion
Oncogene activation is often associated with changes in metabolic parameters including enhanced generation of ROS. 38 ROS are well known for having a dual role as both beneficial and deleterious species. The 'two-faced' character of ROS is supported by numerous evidence that ROS can act as secondary messenger in intracellular signaling cascades and epigenetic modifications, which induce and maintain the oncogenic phenotype of cancer cells; however, ROS can also damage DNA, proteins and lipids to induce cellular senescence and apoptosis. 39 Thus, tumor cells need to protect themselves from an excess of ROS in order to survive. In concordance, hematopoietic cells may undergo p53-mediated apoptosis and/ or p38 mitogen-activated protein kinase-dependent senescence, shortly after expression of oncogenes such as BCR-ABL1, v-Abl, CBFB-MYH11 and RUNX1-ETO. 7, 40 Presumably, only clones capable of dealing with the 'crisis' emerge as leukemic populations and become tolerant to higher levels of oxidative DNA lesions, for example 8-oxoG and DSBs. 3, 4 Accordingly, genes regulating DNA repair mechanisms may be important for 12-14 These mechanisms may be seminal for protection of BCR-ABL1 leukemia cells from the potentially lethal effect of elevated levels of endogenous (ROS-dependent) and exogenous (genotoxic agent-induced) DSBs. Therefore, FANCD2 may protect cells from apoptosis induced by DNA damage and facilitate DSB repair in Ph-positive leukemias. This hypothesis is supported by data showing that downregulation of FANCD2 expression either by siRNA or genetic knockdown reduced the in vitro growth rate and in vivo leukemogenic potential of BCR-ABL1 kinase-positive cell lines, BCR-ABL1-transformed FANCD2À/À murine BMCs and CML-CP and CML-BP CD34 þ cells. We showed that reduced clonogenic potential of BCR-ABL1-transformed FANCD2À/À cells in comparison with BCR-ABL1-positive FANCD2 þ / þ and FANCD2À/À ( þ FANCD2) counterparts was not associated with any specific alterations in stem cell enriched Lin-Sca1 þ Kit þ and early progenitor enriched Lin-Sca1-Kit þ populations. However, Zhang et al. 41 reported that non-transformed FANCD2À/À cells displayed a decline in the size of Lin-Sca1 þ Kit þ pool associated with proliferation disturbances. This discrepancy could be explained by the impact of BCR-ABL1 kinase on LinSca1 þ Kit þ cells and also by the fact that BMCs used in our studies were obtained from the mice pre-treated with 5-FU to enrich the population with stem cells, whereas those used by Zhang et al. 41 were harvested from untreated mice. Although the growth defect in BCR-ABL1-positive FANCD2-deficient cells was not associated with enhanced ROS and increased numbers of oxidized DNA bases, accumulation of excessive DSBs was readily detectable. This suggests that high number of DSBs in BCR-ABL1-positive FANCD2-deficient cells was not dependent on enhanced generation of ROS-induced DSBs, but rather due to inefficient DSB repair. In concordance with this speculation, expression of FANCD2 wt and FANCD2 (S222A) mutant (proficient in DNA repair, but deficient in S phase checkpoint), but not FANCD2(K561R) mutant (deficient in DNA repair, but proficient in S phase checkpoint 18 ) prevented accumulation of DSBs and restored proliferative potential of BCR-ABL1-positive FANCD2À/À cells. These results strongly suggest that FANCD2-Ub is required to catalyze DSB repair and protect BCR-ABL1-positive leukemia cells from the detrimental effect of excessive unrepaired DSBs.
FA cells exhibit hypersensitivity to oxidative stress, which indicates that FA proteins may have a major role in protection against oxidative damage. 42 For example, FANCC and FANCG are found to associate and possibly modulate a variety of proteins, such as cytochrome P450, glutathione S-transferase, Cu/Zn superoxide dismutase and peroxiredoxin-3 to diminish oxidative stress and number of DSBs. 42, 43 ROS also causes multimerization and nuclear complex formation by the core FA proteins necessary for the appearance of FANCD2-Ub. 44 In CML cells, which contain high numbers of ROS-induced DSBs, FANCD2-Ub may become an important player in the protection of leukemia cells from an excess of potentially lethal DNA lesions. In concordance, CML primary cells and BCR-ABL1-transformed cell lines overexpressed FANCD2-Ub in response to endogenous oxidative stress and genotoxic treatment, and ROS scavengers, such as vitamin E and N-acetylcysteine not only reduced the accumulation of DSBs, but also enhanced the growth of BCR-ABL1-positive FANCD2-deficient cells. Our data are seemingly in contrast to these recently reported by Valeri et al., 45 suggesting that BCR-ABL1 disrupts FANCD2-Ub.
However, most of their measurements were performed in BCR-ABL1-positive CD34 þ umbilical cord blood cells 16 h after MMC treatment, thus addressing late stages of DNA damage response; at that time, most MMC-induced DSBs are already repaired in BCR-ABL1-positive cells, whereas parental cells usually display slower and sometimes inefficient repair rate eventually leading to apoptosis.
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FANCD2-Ub is also required during DNA replication stress, for the stability of common fragile sites and to protect ultrafine DNA bridges linking sister chromatids. 47, 48 However, none of these functions appear to have a critical role in Ph-positive leukemias, because the growth of BCR-ABL1-positive FANCD2À/À cells was restored, at least partially by reduction of the number of ROS-induced DSBs. Moreover, the role of FANCD2 in protection from telomere erosion is probably irrelevant here, because BCR-ABL1-positive leukemia cells tolerate short telomeres. 49, 50 In addition, although BCR-ABL1 inhibits FOXO3a transcription factor, it is rather unlikely that the interaction between FANCD2-Ub and FOXO3a is relevant for Ph-positive leukemia cells. 51, 52 In summary, we believe that FANCD2-Ub is required to facilitate the repair of numerous ROS-induced DSBs, which, if unrepaired, may impair the growth of BCR-ABL1-positive leukemia cells. This hypothesis is supported by the observation that restoration of the reading frame of inactivated FANCD1/BRCA2 gene caused acceleration of AML. 53 
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